

Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both

Paul E. Pfeffer, Nasloon Ali, Ruth Murray, Charlotte Ulrik, Trung N. Tran, Jorge Maspero, Matthew Peters
... See all authors 

First published: 17 March 2023 | <https://doi.org/10.1111/all.15711>

Allergy

EUROPEAN JOURNAL OF ALLERGY
AND CLINICAL IMMUNOLOGY

Aims and Methods

Aims

1. Describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R
2. Compare the effectiveness of both classes of treatment in real life.

Outcomes

- **Primary outcome:** Exacerbation rate
- **Secondary outcomes:**
 - Long-term oral corticosteroid use
 - Emergency room visits
 - Hospitalizations

ISAR

Adult severe asthma patients eligible
eligible to receive both Anti-IgE and
Anti-IL5/5R


1:1 matched cohort

Anti-IgE initiated
(n=350)





Anti-IL5 initiated
(n=350)

Associations between biologic therapy and outcomes at post-therapy

Outcomes at post-therapy	IRR
Exacerbation (adjusted for pre-therapy exacerbation, asthma control and BMI)	0.76 (0.64-0.89)
Hospitalization (adjusted for pre-therapy hospitalization, exacerbation, asthma control and BMI)	0.64 (0.38-1.08)
Emergency room admission (adjusted for pre-therapy emergency room admission, exacerbation, asthma control and BMI)	0.94 (0.61-1.43)



Determining the 'right' biologic when patients are eligible for both Anti-IgE and Anti-IL5/5R – a matched analysis



Conclusions



In real-life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes.





Anti-IL5/5R was superior in reducing asthma exacerbations and LTOCS use.



These findings can **assist treatment decisions** and add to the growing body of robust real-life data on biologics.

Recap



Thank you!